A novel chemical inhibitor suppresses breast cancer cell growth and metastasis through inhibiting HPIP oncoprotein

Pengyun Li1,2, Shengjie Cao2, Yubing Huang1,2, Yanan Zhang1, Jie Liu1, Xu Cai2, Lulu Zhou2, Jianbin Li1,3, Zefei Jiang3, Lihua Ding1,2, Zhibing Zheng2, Song Li2 and Qinong Ye1

© The Author(s) 2021

Increasing evidence suggests the pivotal role of hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP/PBXIP1) in cancer development and progression, indicating that HPIP inhibition may be a promising target for cancer therapy. Here, we screened compounds inhibiting breast cancer cell proliferation with HPIP fused with green fluorescent protein as a reporter. A novel agent named TXX-1-10 derived from rimonabant, an antagonist of cannabinoid receptor 1 with anticancer effects, has been discovered to reduce HPIP expression and has greater inhibitory effects on breast cancer cell growth and metastasis in vitro and in vivo than rimonabant. TXX-1-10 regulates HPIP downstream targets, including several important kinases involved in cancer development and progression (e.g., AKT, ERK1/2, and FAK) as well as cell cycle-, apoptosis-, migration-, and epithelial-to-mesenchymal transition (EMT)-related genes. Consistent with the results of anticancer effects, genome-wide RNA sequencing indicated that TXX-1-10 has more significant effects on the expression of genes related to DNA replication, cell cycle, apoptosis, cell adhesion, cell migration, and invasion than rimonabant. In addition, TXX-1-10 significantly regulated genes associated with the cell growth and extracellular matrix organization, many of which were shown to be regulated by HPIP. Moreover, compared with rimonabant, TXX-1-10 greatly reduces blood-brain barrier penetrability to avoid adverse central depressive effects. These findings suggest that HPIP inhibition may be a useful strategy for cancer treatment and TXX-1-10 is a promising candidate drug for cancer therapy.

Cell Death Discovery (2021) 7:198; https://doi.org/10.1038/s41420-021-00580-3

INTRODUCTION

As one of the most common heterogeneous diseases among women, breast cancer highly displays diversification in terms of its presentation, disease progression, pathological characteristics, and clinical response [1, 2]. Although great progress has been made in clarifying molecular features and pathogenesis underlying breast tumorigenesis, and multiple therapeutic strategies have been employed in individual treatment, some types of breast cancer patients develop with aggressive characteristics and have a poor prognosis [3, 4]. Therefore it is necessary to investigate the factors regulating cancer progression and develop novel molecules for cancer treatment.

The PI3K/Akt/mTOR and RAS-RAF-MEK-ERK signaling pathways are hyperactivated in a high percentage of tumors, including epithelial ovarian, glioblastoma, breast, lung, and renal cancers [5–7]. Increasing studies have been focused on the development of small-molecule inhibitors targeting components of PI3K/Akt/mTOR and RAS-RAF-MEK-ERK signaling as cancer therapeutics [8]. Recently, AKT inhibition using small-molecule inhibitors, such as AZD5363 and GSK690693 have been studied in preclinical setup and evaluated in many clinical trials to block human tumors [9]. ERK inhibitors such as Ulixertinib were used for the treatment of various advanced/metastatic solid tumors [10]. However, clinical efficacy using single molecules directly inhibiting Akt or ERK signaling was shown to have a limited pharmaceutical effect on cancer due to the induction of resistance [9, 11]. Moreover, several therapies have been discontinued because of the development of side effects, such as rash, hyperglycemia, and hemolytic toxicity after intravenous injection [6], implying the need for more innovative approaches to achieve inhibition of Akt or ERK signaling for cancer treatment with minimal side effects.

Hematopoietic PBX-interacting protein (HPIP), a corepressor for the transcription factor PBX, is involved in organogenesis and tumorigenesis [12, 13]. We and others have previously reported the critical role of HPIP for the progression in various human cancer types, including infiltrative ductal carcinoma [14], liver cancer [15], gastric cancer [16], and colorectal carcinoma [17]. HPIP modulates hepatocellular carcinoma cell growth, invasion, epithelial-mesenchymal transition (EMT), and metastasis through regulating the AKT, ERK, and mTOR signaling [15]. HPIP is also an activator of focal adhesion kinase (FAK) to regulate cell adhesion and migration [14]. A very recent study shows that HPIP promotes the G2/M transition of the cell cycle by stabilizing cyclin B1 [18]. Due to the importance of HPIP in cancer, we screened chemical compounds inhibiting breast cancer cell proliferation with HPIP fused with green fluorescent protein as a reporter. A novel small
molecule named TXX-1-10 derived from rimonabant, an antagonist for the cannabinoid receptor CB1 was identified to reduce HP/IP expression together with its downstream targets and inhibit tumor growth and metastasis with great efficacy than rimonabant. In addition, compared with rimonabant, TXX-1-10 considerably reduces blood-brain barrier penetrability, thereby avoiding adverse central depressive effects.

RESULTS
Identification of the small chemical molecule TXX-1-10 that inhibits HP/IP expression by cell-based screening
Since the crucial role of HP/IP in cancer development and progression, we developed an image-based screening model with HP/IP-copGFP (green fluorescent protein)-overexpressing ZR75-1 cells to screen small chemical molecules that decrease both fluorescence signal intensity and cell viability. The screened molecules were further quantitatively validated by Western blot (WB) with anti-HP/IP (Fig. 1A). Interestingly, the primary screen based on a library of over 600 compounds revealed that molecules derived from rimonabant significantly reduced both fluorescence intensity and cell viability (Supplementary Fig. 1A). Among these compounds, TXX-1-10 (CB1-8) exhibited the most significant effect on reducing cell viability, fluorescence intensity, and HP/IP protein expression (Fig. 1B-D and Supplementary Fig. 1B, C). Quantitative reverse-transcription PCR (RT-qPCR) and western blot analysis indicated that TXX-1-10-reduced HP/IP mRNA and protein levels in a dose-dependent manner (Fig. 1E). Consistent with the results showing that HP/IP-activated AKT and ERK1/2 [15], TXX-1-10-repressed AKT and ERK1/2 phosphorylation in a dose-dependent manner (Fig. 1F). In addition, HP/IP knockout decreased the sensitivity of ZR75-1 cells to TXX-1-10 as well as the effect of TXX-1-10 on reducing AKT and ERK1/2 phosphorylation (Fig. 1G, H). Taken together, these data demonstrate that TXX-1-10 reduces HP/IP expression and exerts antiproliferation effect in a HP/IP-dependent manner.

TXX-1-10 inhibits cancer cell proliferation
Next, we investigated the effect of TXX-1-10 on cancer cell viability in 19 cancer cell lines and five normal cell lines. The IC50 values in various cancer cell lines varied from 2.2 to 7.9 µM, indicating that TXX-1-10 decreases cancer cell viability without cell-type specificity (Fig. 2A and Supplementary Fig. 1D). The IC50 values in the normal cell lines ranged from 19.7 to 27.5 µM, suggesting that cancer cells are more sensitive to TXX-1-10 than normal cells. We next explored the level of HP/IP in the panel of breast cancer cell lines, which was significantly reduced with TXX-1-10 treatment. In contrast, the expression of HP/IP in the normal counterpart HMEC cells was not decreased with TXX-1-10 treatment (Supplementary Fig. 1E). In addition, cell proliferation assay and colony formation assay showed that TXX-1-10 exhibited a more effective inhibition compared with rimonabant in MDA-MB-231 and ZR-751 cells (Fig. 2B, C).

Since rimonabant was withdrawn from the market because of its neuropyschiatric adverse events [19], we detected the blood-brain barrier (BBB) permeability of rimonabant and TXX-1-10. Compared with rimonabant, TXX-1-10 exhibited a dramatic reduction of logBB, S + logP and S + logD predicted by ADMET Predictor 8.1 program (Supplementary Fig. 3). TXX-1-10 showed a 15-fold decrease in BBB permeability than rimonabant in rat brain uptake assay, implying that TXX-1-10 possessed little psychiatric side effects compared with rimonabant (Supplementary Fig. 4). Taken together, these data demonstrated that TXX-1-10 reduces cancer cell proliferation with reduced BBB permeability.

TXX-1-10 induces G1 cell cycle arrest and apoptosis in breast cancer cells
Since antitumor drugs eliminate tumor cells predominantly by triggering apoptosis and inducing cell cycle arrest [20, 21], we next examined the effect of TXX-1-10 on breast cancer cell cycle and apoptosis. Compared with the vehicle, TXX-1-10 increased the proportion of cells in G0/G1 phase and decreased the proportion of cells in S-phenotype and G2/M-phenotype of both ZR-751 and MDA-MB-231 in a dose-dependent manner, suggesting that TXX-1-10 induces G1 cell cycle arrest, we examined the expression of several important cell cycle-related proteins. Consistent with the results of TXX-1-10-induced G1 cell cycle arrest, TXX-1-10 significantly reduced the expression of the G1/S phase marker cyclin D1 and increased the levels of p27 and p21, two major regulators of G1/S phase transition. However, TXX-1-10 did not alter cyclin B1 expression, which is predominantly expressed during G2/M phase (Fig. 3B). Next, we determined whether TXX-1-10 regulates apoptosis of breast cancer cells. Compared with the control, TXX-1-10 significantly induced the apoptosis of ZR-751 (from 15.8 to 42.1%) and MDA-MB-231 (from 10.5 to 47.2%) cells (Fig. 3C). In consistent with the results of TXX-1-10-induced apoptosis, TXX-1-10 inhibited the expression of the antiapoptotic protein Bcl-2, and promoted the expression of BAX, cleaved PARP, and cleaved-caspase 3 that are the apoptotic proteins in a dose-dependent manner (Fig. 3D). However, rimonabant did not induce apoptosis or alter the expression of these apoptosis-related proteins (Fig. 3C, D). Taken together, these data demonstrated that TXX-1-10 induce G1 cell cycle arrest and apoptosis in breast cancer cells.

TXX-1-10 inhibits breast cancer cell migration and invasion in vitro
Tumor metastasis is the most common leading cause of breast cancer-related mortality and remains the greatest challenge in clinical cancer management, so it is urgent to develop novel potential candidates to cope with metastatic progression [4, 22, 23]. Next, we examined the effect of TXX-1-10 on migration and invasive capacity in breast cancer cells. Wound-healing assay and matrigel invasion assay showed that TXX-1-10 significantly inhibited the migration and invasion of ZR-751 and MDA-MB-231 in a dose-dependent manner (Fig. 4A, B). In contrast, rimonabant had little effect on the migration and invasion of breast cancer cells. Since HP/IP has been reported to be an activator of focal adhesion kinase (FAK) to regulate cell adhesion and migration [14], and phosphorylation of FAK (Tyr397) and Paxillin (Ser178) promote cancer cell migration and invasion [24], we investigated whether TXX-1-10 regulates FAK and Paxillin [14]. Indeed, TXX-1-10 inhibited the phosphorylation of FAK (Tyr397) and Paxillin (Ser178) in a dose-dependent manner, and rimonabant had less inhibitory effect compared with TXX-1-10 (Fig. 4C). As migration defects are often associated with markers of EMT [23], and HP/IP has also been shown to promote renal cell carcinoma migration and invasion with increased EMT [25]. Next, we found that TXX-1-10 significantly increased the expression of the epithelial marker E-cadherin. In comparison, the expression of mesenchymal marker N-cadherin, Vimentin, snail, and Slug was significantly reduced with TXX-1-10 treatment (Fig. 4D). ALDH1-high cells are considered to be breast cancer stem cells (CSCs). Neither TXX-1-10 nor rimonabant showed the effect on ZR75-1 and MDA-MB-231 cell stenness (Supplementary Fig. 5A, B). Taken together, these data indicated that TXX-1-10 inhibits breast cancer cell migration and invasion.

RNA-Seq reveals TXX-1-10 regulating expression of genes related to cell growth and metastasis
Given TXX-1-10 as a potent tumor-suppressive agent, we investigated the impact of TXX-1-10 on global gene expression using RNA sequencing (RNA-seq) (Fig. 5A and Supplementary Fig. 7A, B). RNA-seq assay demonstrated an extensive overlap of genes commonly regulated by TXX-1-10 and rimonabant. The expression of 78.6% of the genes changed in rimonabant treatment was
recapitulated in the TXX-1-10-treated cells (Supplementary Fig. 7C).

Analysis of common regulated genes by TXX-1-10 and rimonabant showed that TXX-1-10 and rimonabant generally exerted inhibitory effects on diverse tumor-associated biological processes, such as DNA replication, focal adhesion, and cancer-related pathways including cGMP-PKG signaling pathway, PI3K-Akt signaling pathway, and HIF-1 signaling pathway (Fig. 5B). TXX-1-10 exhibited a more effective inhibition of these processes compared with rimonabant. KEGG analysis of TXX-1-10-regulated
marker)-positive tumor cells (Fig. 6D), in agreement with the stimulatory effect on the amount of cleaved caspase-3 (apoptosis marker)-, and HPIP-positive tumor cells, and a more significant amount of Ki67 (proliferation marker)-, CD31 (endothelial cell marker) gene expression in mice (Fig. 6A). In vitro, the TXX-1-10 showed a stronger inhibitory effect on breast cancer growth and metastasis in vivo. Consistent with the results of the effects of TXX-1-10 and rimonabant on breast tumor growth and metastasis, many of which are regulated by HPIP.

Collectively, these findings demonstrated TXX-1-10-modulated signaling pathways, such as DNA replication, cell cycle, and focal adhesion, which were essential for cancer cell proliferation and/or metastasis (Fig. 5C). GO enrichment analysis showed that TXX-1-10-regulated genes also implicated in the cancer cell biological processes, such as DNA replication (GO: 0006260), cell cycle (GO: 0007049), and apoptosis (GO: 0042981) (Fig. 5D). Importantly, some of these transcripts regulated by TXX-1-10 and rimonabant were further validated by qRT-PCR, and TXX-1-10 exhibited a greater impact on the expression of genes involved in DNA replication, cell cycle, apoptosis, cell adhesion, and cell migration, invasion and metastasis than rimonabant (Fig. 5E, F and Supplementary Fig. 7D–H). It has been reported that genes related to skeletal system development, cell growth, and extracellular matrix organization related to cell migration, invasion, and metastasis were regulated in HPIP-deficient transcriptome [26]. We also found that the expression of those 68 genes were also changed in the TXX-1-10-treated cells (Fig. 5G). Collectively, these findings demonstrated TXX-1-10 modulates the expression of many genes implicated in cancer cell growth and metastasis, many of which are regulated by HPIP.

**TXX-1-10 suppresses breast tumor growth and metastasis in vivo**

Since the TXX-1-10 exhibits a stronger inhibitory effect than rimonabant on breast cancer cell proliferation and motility in vitro, we examined the effect of TXX-1-10 and rimonabant on breast cancer growth and metastasis in vivo. Consistent with the results in vitro, the TXX-1-10 showed a stronger inhibitory effect on breast tumor growth than rimonabant without affecting the body weight of mice (Fig. 6A–C). Compared to the rimonabant groups, the TXX-1-10 groups showed a more significant inhibitory effect on the amount of K67 (proliferation marker)-, CD31 (endothelial cell marker)-, and HPIP-positive tumor cells, and a more significant stimulatory effect on the amount of cleaved caspase-3 (apoptosis marker)-positive tumor cells (Fig. 6D), in agreement with the results of the effects of TXX-1-10 and rimonabant on breast tumor growth in vivo. Furthermore, the lung metastasis of the TXX-1-10 treatment group was significantly decreased compared with that of the rimonabant group (Fig. 7A), and the survival rates of the TXX-1-10 (P < 0.05) groups were higher than those of the rimonabant groups (Fig. 7B). Taken together, these data suggested that the TXX-1-10 inhibits breast tumor growth and lung metastasis, and TXX-1-10 shows a more potent anticancer effect than rimonabant.

**DISCUSSION**

In the present study, we developed a novel agent named TXX-1-10, a derivative of rimonabant, which significantly reduces HPIP expression and regulates HPIP downstream targets, such as AKT, ERK1/2, and FAK as well as cell cycle-, apoptosis- and migration/invasion-related genes (Fig. 7C). The TXX-1-10 has a more effective inhibition on breast cancer cell proliferation, migration, invasion, and metastasis in vitro and in vivo than rimonabant. Genome-wide RNA sequencing indicated TXX-1-10 has more significant effects on the regulation of the expression of genes involved in cancer cell growth and metastasis than rimonabant. Furthermore, compared with rimonabant, the blood-brain barrier permeability of TXX-1-10 is decreased to avoid psychotropic side effects. These findings suggest that the TXX-1-10 can be a candidate drug for inhibition of cancer growth and metastasis.

Since HPIP modulates cancer cell growth, invasion, epithelial-mesenchymal transition (EMT) and metastasis through regulating various genes, including AKT, ERK, FAK, and mTOR signaling [13–15, 25, 27]. Herein, we found TXX-1-10-reduced AKT and ERK1/2 phosphorylation in a dose-dependent manner. Moreover, knock-out of HPIP alleviated the effect of TXX-1-10 on AKT and ERK inhibition, demonstrating the role of HPIP in TXX-1-10-regulated AKT and ERK signaling. It has also been reported that HPIP interacts with ERs and increasing ERα target genes expression, including pS2 and cathepsin D through activation of MAPK and AKT [13]. In this paper, we also explored whether TXX-1-10 treatment affects ERα expression, HPIP-ERα cooperation as well as...
Fig. 3  TXX-1-10 induces G1/S cell cycle arrest and apoptosis in breast cancer cells. A The cell cycle distributions of ZR75-1 and MDA-MB-231 cells treated with TXX-1-10, Rimonabant, or vehicle for 48 h. The cell cycle was evaluated by flow cytometry after staining with propidium iodide (PI) for 30 min at 37 °C in dark. Histograms show the cell cycle distributions of ZR75-1 and MDA-MB-231 cells (right panel).

B Representative immunoblot assay of ZR75-1 and MDA-MB-231 cells treated as in A with the indicated antibodies.

C Representative images of flow cytometry analysis of apoptosis in ZR75-1 and MDA-MB-231 cells treated as in A. Statistical analysis of apoptosis rates was shown in the right panel.

D Representative immunoblot assay of ZR75-1 and MDA-MB-231 cells from C with the indicated antibodies. Statistical significance was assessed by two-tailed Student’s t test. *p < 0.05, **p < 0.01 versus the corresponding control.
the modulation of ERα target genes. TXX-1-10 treatment showed no effect on HPIP-ERα interaction (Supplementary Fig. 6A); however, TXX-1-10-reduced the expression of pS2 and cathepsin D, two ERα target genes (Supplementary Fig. 6B), which may be modulated by inhibition of MAPK and AKT with TXX-1-10 treatment (Supplementary Fig. 5D). In addition, overexpression of HPIP reversed the inhibitory effect of TXX-1-10 on pS2 and cathepsin D.

In the last few decades, an increasing number of studies have revealed the aberrant expression of CB1 receptor in numerous types of tumors, which is related to cancer prognosis and disease outcome [28, 29]. Several authors have demonstrated that CB1 antagonist rimonabant exerts an anticancer activity in various cancers, including breast cancer [30] and colon cancer [31, 32]. Here, we have also shown that rimonabant suppresses the breast cancer cell proliferation and tumor growth both in vitro and in vivo. However, it was found that rimonabant had neuropsychiatric adverse events, such as alteration of emotional behaviors and cognitive function, which led to its withdrawal from the market [19]. In this study, we developed TXX-1-10, a derivative of...

Fig. 4 TXX-1-10 inhibits breast cancer cell migration and invasion. A Wound-healing assay of ZR75-1 and MDA-MB-231 cells treated with TXX-1-10, rimonabant or vehicle control (DMSO) following mitomycin C (1 μM) treatment at the indicated time. Histograms show the relative cell migration (right panel). Scale bar: 100 μm. B Transwell assay of MDA-MB-231 cells treated as in A. Invasive cells were fixed and stained with crystal violet. Histograms show the relative cell invasion (bottom). C Western blot assay of ZR75-1 and MDA-MB-231 cells treated with increasing concentrations of TXX-1-10 for 24 h with the indicated antibodies. Data shown are mean ± SD of triplicate measurements that have been repeated three times with similar results. Statistical significance was assessed by two-tailed Student’s t test. *p < 0.05, **p < 0.01 versus the corresponding control.
rimonabant with a more potent antitumor capacity in inhibiting tumor growth and metastasis than rimonabant both in vitro and in vivo. The antiproliferative effects of TXX-1-10 are accompanied by substantial apoptotic processes along with increased caspase-3-mediated PARP cleavage as well as the reduced ratio of Bcl-2/Bax and subsequent G1 cell cycle arrest. Although rimonabant also induced G1 cell cycle arrest, no effects on cell apoptosis and apoptotic-related proteins were observed. In addition, TXX-1-10 inhibits cancer metastasis via decreasing the phosphorylation and catalytic activity of proteins related to the FAK signal pathway.
whereas rimonabant showed a little suppressive effect of cancer metastasis as well as related proteins. Furthermore, RNA-sequencing analysis also reveals that TXX-1-10 generally leads to a more significant suppression or stimulation of genes than rimonabant involved in tumor-associated biological processes.

Given the side effects of rimonabant, we detected the BBB permeability of TXX-1-10. The results indicate that the latter would not exert unwanted psychotropic effects as the three-position of the pyrazole ring of rimonabant is structurally modified with a higher hydrophobic quaternary ammonium salt group. Indeed, the physicochemical properties predicted by the ADMET predictor 8.1 suggest that TXX-1-10 is a more promising candidate drug for cancer treatment. For this reason, we further conducted to combine TXX-1-10 with other strategies.

Collectively, we developed a novel agent named TXX-1-10, which significantly reduces HIPPI expression and regulates HIPPI downstream targets. TXX-1-10 has a more effective inhibition on breast cancer cell proliferation, migration, invasion, and metastasis in vitro and in vivo than rimonabant. The gene-expression signature also reflects the tumor-suppressive properties of TXX-1-10 on diverse tumor processes, suggesting HIPPI may be an attractive therapeutic target for cancer therapy. Further investigation is warranted to evaluate the efficacy of TXX-1-10 as a clinical candidate drug or in combination with other strategies for cancer treatment.

MATERIALS AND METHODS

Chemical synthesis

The chemical structures and synthetic schemes for TXX-1-10 are presented in Supplemental Fig. 2A. Detailed synthetic procedures are provided below.

Preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-formyl chloride (compound b)

Sulfoxide (20 ml) was added into a stirred solution of rimonabant carboxylic acid (3.86 g, 10.12 mmol) in toluene (20 ml). The mixture was stirred at 130 °C for 6 h and evaporated to dryness between 110–130 °C to get the crude product.

Preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(3-pyridylmethyl)-1H-pyrazole-3-carboxamide (compound c)

3-aminomethylpyridine (0.64 g, 3.0 mmol) dissolved in dichloromethane (8 ml) was added to CH3I (840 mg, 5.92 mmol). The mixture was stirred at room temperature overnight. Then the mixture was poured into water (100 ml) and extracted with DCM three times. The organic phase was washed, evaporated, and purified to afford the title compound (1.72 g, yield 60.3%).$^{1}$H-NMR (400 MHz, DMSO-d6) $\delta$ 2.39 (s, 3H), 4.76–4.77 (d, 2H), 7.06–7.42 (m, 9H), 7.66–7.68 (m, 1H), 7.85 (s, 1H), 8.56–8.57 (m, 1H), ESI-MS m/z: 471.2 [(M + H)$^+$].

Preparation of TXX-1-10

Compound 3 (920 mg, 1.96 mmol) dissolved in N-methylpyrazolidone (8 ml) was added to CH3I (840 mg, 5.92 mmol). The mixture was stirred at 35–40 °C for 2 h. The crude product was purified by recrystallization to afford title compound (972 mg, yield 39.1%).$^{1}$H-NMR (400 MHz, DMSO-d6) $\delta$ 2.50 (s, 3H), 2.29 (s,3H), 4.36 (s,3H), 7.25–7.27 (m,2H), 7.45–7.47 (m,2H), 7.59–7.62 (dd,1H), 7.77–7.83 (m,2H), 8.04–8.08 (m,1H), 8.08–8.12 (m,1H), 8.68–8.74 (m,1H), 9.54 (s,1H), 11.25 (s,1H), ESI-MS m/z: m/z: 473.5 [(M + H)$^+$].

Cell lines and reagents

All cell lines used in this study were purchased from the American Type Culture Collection (ATCC, Manassas, Virginia, USA). MCF-7, ZR-751, T-47D, MDA-MB-231, MDA-MB-468, MDA-MB-436, A549, H1299, HepG2, SMCC7721, 786-O, HeLa, PANC-1, BxPC-3, 8305 C, 293 T, LO2, HMEC, and NIH3T3 cells were cultured in DMEM (high glucose) containing 25 mM glucose (Invitrogen), 10% FBS (HyClone), 1% penicillin (Invitrogen), and 1% streptomycin (Invitrogen). All cell lines were maintained in a humidified incubator at 37 °C and 5% CO2. TXX-1-10 and other novel derivatives were designed and synthesized in the laboratory of Professor Zhibin Zheng at National Engineering Research Center for the Emergency Drug through the chemical modification of rimonabant. Compounds were dissolved in DMSO and diluted in normal saline for cell culture studies.

Rimonabant(#T1519L) was purchased from Targetmol, USA; anti-β-actin (#20536-1-AP), anticynbin D1(#26939-1-AP), anti-p21(#10355-1-AP), anti-p27...
Fig. 6 TXX-1-10 represses breast tumor growth in vivo. A. Bioluminescent MDA-MB-231 cells were subcutaneous transplanted into BALB/c mice. Mice were treated with vehicle control, rimonabant (30 mg/kg) or TXX-1-10 (30 mg/kg) 5 days after xenograft as indicated and tumor size was monitored every other day. Photograph of tumors and tumor weight of animals administrated with TXX-1-10, rimonabant or vehicle control are shown (n = 8 per group). B. Representative bioluminescent images of animals were taken at the day 0, 7th-, 14th-, and 21st-day postbioluminescent MDA-MB-231 xenografts (left panel). Quantification of tumor cells in mice body was performed with bioluminescence analysis (right panel) (n = 8 per group). C. Body weight of BALB/c mice treated with vehicle control, rimonabant (30 mg/kg) or TXX-1-10 (30 mg/kg) as indicated are shown (n = 8 per group). D. Representative images of H&E, Ki67, cleaved-caspase 3, HPIP, and CD31 immunohistochemical (IHC) staining in harvested tumors from each group are shown (left panel). Histograms show the quantification of Ki67+, cleaved-caspase 3+ cells, CD31+ cells, and HPIP+ cells (right panel). Scale bar: 50 μm. Data shown are mean ± SD of triplicate measurements that have been repeated three times with similar results. p values were determined by two-tailed Student’s t test (*p < 0.05, **p < 0.01). Statistical significance was assessed by two-tailed Student’s t test. (ns not significant; *p < 0.05, **p < 0.01). *p < 0.05 on the final day A, B.

Plasmids and lentiviruses construction
Stable ZR75-1 cell line overexpressing HPIP-copGFP was constructed by inserting PCR-amplified HPIP fragment linked with copGFP tag at the carboxyl terminus into a pCDH plasmid (System Biosciences) using the following primers: HPIP CDS: 5′-GCTCTAGAGCCACCATGGCCTCCTGCCCAG-3′.

anti-BAX (#50599-2-Ig), anti-Bcl-2 (#12789-1-AP), anti-PARP (#13371-1-AP), anti-Cyclin B1 (#55004-1-AP), anti-HPIP (#12102-1-AP), anti-Ki67 (#27309-1-AP), anti-FAK (#12636-1-AP), anti-ERK (#67170-1-Ig), anti-AKT (#10176-2-AP), anti-Paxillin (#22172-1-AP), anti-pS2 (#13734-1-AP), anti-ERα (#21244-1-AP), anti-Vimentin (#10366-1-AP), anti-Slug (#12129-1-AP), anti-Flag (#66006-2-Ig), anti-E-Cadherin (#20874-1-AP), anti-N-Cadherin (#22018-1-AP) and anti-Cathepsin D (#55021-1-AP) were purchased from Proteintech; anti-Cleaved Caspase-3 (#9661), anti-Caspase 3 (#9662), anti-phos-FAK(Y397) (#8556), anti-phos-AKT (#66008-3-Ig), anti-HA (#66006-2-Ig), anti-E-Cadherin (#20874-1-AP), anti-N-Cadherin (#22018-1-AP) and anti-Cathepsin D (#55021-1-AP) were purchased from Cell Signaling Technology; anti-phos-Paxillin(S178) (#sc-365020), and anti-phos-ERK (T202/Y204) (#sc-136521) were purchased from Santa Cruz Biotechnology.
ACTCTGATAA-3’ (forward) and 5’-CGGGATCCGCCCCGGTGGTGGTGGTG
GCTAT-3’ (reverse); CopGFP CDS: 5’-CGGGATCCATGGAGAGCGACGAGAGC
G-3’ (forward) and 5’-ATAAGAATGCGGCCGCGCGAGATCCGGTGGAGCC-3’
(reverse). The 293 T cells were inoculated into six-well plates to 70–
90% confluence degree, the DNA-lipid complex was added into the cells
according to the manufacturer’s instructions (Invitrogen), and the cells
were incubated at 37 °C for 2–4 days to collected lentivirus. Stable cell lines
were selected with puromycin 48 h after infection.

Estimation of brain uptake
Brain uptake clearance was estimated using a sample pooling method
according to a previous study [35]. TXX-1-10 and rimonabant, at 5 mM,
were injected via the tail vein into male Sprague-Dawley rats (body weight
= 200 g ± 15 g). First, a rapid bolus injection was conducted at a flow rate
of 150 ml/h for 5 s, followed by a continuous bolus injection at a flow rate
of 0.5 ml/h. Venous blood was taken from heparin sodium anticoagulant
tubes after administration. The drug concentration in plasma and brain
tissue samples were measured by LCMS-8060 liquid chromatography-mass
spectrometry (Shimadzu, Japan).

Cell viability and colony formation assays
For cell viability assay, anchorage-dependent cell viability was evaluated by
the CCK-8 Kit (Dojindo Laboratories) according to the manufacturer’s
instructions. Cancer cells in complete cell culture medium were seeded in
96-well plates (100 µl per well) at 4000 cells/well to adhere overnight and
were then treated. The compounds were prepared in a complete cell
culture medium and 100 µl of 2× treatment-containing medium were
added to each well for 48 h. Subsequently, 100 µl of cell culture medium
containing 10% CCK-8 solution was added to cultured cells, and the
mixture was incubated at 37°C and 5% CO2 for 2 h. The OD values were
measured at 450 nm using a microplate reader. For colony formation assay,
cancer cells treated with TXX-1-10 or vehicle (DMSO) for 48 h were plated
in twelve-well dishes in triplicate at 2000 cells per well to grow for
10–14 days. The number of colonies with more than 1.0 mm diameters was
scored.

Cell migration and invasion
For cell migration assay, the confluent monolayers of cells were
mechanically scratched using a 200 µl pipette tip. The debris were washed
with PBS three times and treated with DMSO or compounds in DMEM
(high glucose) without FBS accompanied with mitomycin C (1 µM)
treatment. The migrated cells were counted after taking images at 0 and
12 h in the same place. For cell invasion assay, 10 µl liquid Matrigel (BD
Biosciences) melted on the ice was added dropwise to the upper surface of
the transwell chamber (Corning). Cancer cells were washed with PBS three
times and were added to each well with DMSO or compounds treatment-
containing medium at 10,000 cells per well accompanied with mitomycin
C (1 µM) treatment. After 24 h, 4% paraformaldehyde was used to fix the

Fig. 7 TXX-1-10 represses breast tumor metastasis in vivo. A Bioluminescent MDA-MB-231 cells were tail vein injected into BALB/c mice. Mice were treated with vehicle control, rimonabant (30 mg/kg) or TXX-1-10 (30 mg/kg) as indicated. Representative images were taken at the 0, 7th, 14th, and 21st day, respectively (left panel). Histograms show the quantification of metastatic cells in the whole body determined by bioluminescence analysis (right panel) (n = 6 per group). B Survival rates of nude mice treated as in A were shown (n = 6 per group). C Proposed model for TXX-1-10 inhibition of breast cancer growth and metastasis. TXX-1-10 decreases HPiP expression, leading to the regulation of inducing cell cycle arrest, apoptosis and inactivation of the metastasis-associated gene, causing growth and metastasis inhibition of breast cancer. p values were determined by two-tailed Student’s t test (*p < 0.05, **p < 0.01). Statistical significance was assessed by two-tailed Student’s t test. (ns not significant; *p < 0.05, **p < 0.01). **p < 0.01 on the final day A, B.
cells invading the matrix gel membrane, and then the cells were stained with crystal violet. The number of the invaded cells was counted after taking photographs.

Cell cycle and apoptosis
Cancer cells (1 × 10^6 cells) were cultured in six-well dishes to adhere overnight and were then treated with compound for 36 h. For cell cycle analysis, cells were fixed in 70% ethanol overnight, washed with PBS three times, and incubated with 500 µl RNase A (0.2 mg/mL) in PBS for 30 min. Propidium iodide was then added to the cell suspension. Samples were analyzed by a FACS caliber Flow Cytometer (Becton Dickinson). Alternatively, the cells were labeled with propidium iodide and annexin V according to the manufacturer’s instructions (KeyGen Biotech).

Quantitative reverse-transcription PCR (RT-qPCR)
The samples were homogenized with TRizol Reagent (Invitrogen), vortexed for 1 min with 200 µl chloroform and centrifuged at 1.2 × 10^5 rpm for 15 min at 4 °C. The upper aqueous phase (containing RNA) was precipitated with 400 µl isopropanol at room temperature for 10 min and centrifuged at 1.2 × 10^5 rpm for 10 min at 4 °C. The RNA pellets were washed with 70% (v/v) ethanol and then washed with 100% (v/v) ethanol. Then the RNA pellets air-dried and dissolved in 50 µl nuclease-free water. Then 2 µg of total RNA reverse-transcribed to cDNA according to the manufacturer’s recommendation (Takara).

RNA-Seq
A minimum of 3 µg of total RNA was oligo (dT) selected using the Dynabeads mRNA purification kit (Invitrogen). NEBNext UltraTM RNA Library Prep Kit for Illumina® (NEB, USA) was used to generate a sequencing library. In short, the mRNA was extracted and then purified from total RNA. Double-stranded cDNA was synthesized with these short fragments as templates. The cDNA was end-repaired, ligated to Illumina adapters, size selected on agarose gel (≈250 bp), and PCR amplified. The cDNA library was sequenced on an Illumina HiSeq 6000 sequencing platform (BerryGenomics). The gene-expression levels for each transcript of the exon model were estimated as the number of reads per kilobase per million mapped reads (RPKM) using only uniquely mapped reads in exonic regions. A gene is considered significantly differentially expressed if its expression differs between any two samples with the fold change >2 and the p value < 0.05 as calculated by Cufflinks. The RNA-Seq data are available at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession ID (GSE166371).

ALDEFLUOR assay
MDA-MB-231 and ZR75-1 cells were collected and suspended in ALDEFLUOR assay buffer. Each sample was treated with 50 mmol/l diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as a negative control. Each sample was treated with containing ALDH substrate (StemCell Technologies) and incubated for 45 min at 37 °C. Cells were analyzed on a flow cytometer (BD Biosciences). FACS data were analyzed with FlowJo software (Treestart).

Animal models for tumor growth and metastasis
Animal studies were approved by the Institutional Animal Care Committee of Beijing Institute of Biotechnology. Nude mice were purchased from Vital River Laboratory Animal Technology (Beijing) and housed in an SPF animal facility. For tumor xenografts, 5 × 10^6 MDA-MB-231-Luciferase cells were injected subcutaneously into the axilla of 6-week-old female nude mice. This experiment was terminated when the maximum tumor size reached ∼50 mm^3, and the tumor size was measured at the indicated time using calipers. The tumor volume was estimated according to the following formula: volume = (longest diameter × shortest diameter)^2/2. When the tumors reached a volume of ∼50 mm^3, the mice were randomly divided into groups and intraperitoneally injected with rimonabant (30 mg/kg) and TXX-1-10 (30 mg/kg) with an equivalent volume of saline injected in control animals.

Immunohistochemistry
Paraffin sections (3 mm) were mounted on Plus slides and dried in a 60 °C oven. The slides were placed on a Leica BondMax Immunostainer. Antibodies were optimized with a predetermined staining protocol: Ki67, 1:800; CD31 Rabbit mAb 1:500; HPIP Rabbit mAb, 1:500, and cleaved-caspase-3 (Asp179), 1:1000. Slides were dehydrated and cover-slipped with Cytoseal 60 (Richard-Allan Scientific) mounting medium.

Statistical analysis
All in vitro experiments were performed in triplicate and repeated three times. Differences between variables were assessed by χ^2 analysis, two-tailed Student’s t test, log-rank test. The SPSS software 13.0 or GraphPad PRISM 6 (GraphPad) statistical software package is used to perform all statistical analyses. The data are expressed as the mean ± standard deviation, and P < 0.05 was considered statistically significant. In all assays, P < 0.05 was considered statistically significant.

DATA AVAILABILITY
All data generated or analyzed during this study are included in this published article and its supplementary information files.

REFERENCES
1. O’Sullivan CC, Loporini CL, Haddad TC. Updates in the evaluation and management of breast cancer. Mayo. Clin. Proc. 2018;93:794–807.
2. Thorat MA, Cuzick J. Preventing invasive breast cancer using endocrine therapy. Breast. 2017;34:547–554.
3. Morrow M, Schmitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat. Rev. Clin. Oncol. 2015;12:227–38.
4. Filippidis D, Mavrogogenis AF, Mazioti A, Palalias K, Megaloikonomos PD, Papa- gelopoulos PJ, et al. Metastatic breast disease from breast cancer: a review of minimally invasive techniques for diagnosis and treatment. Eur. J. Orthop. Surg. Traumatol. 2017;27:729–36.
5. Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res. 2019;79:1019–31.
6. Samatar AA, Poulikakos PI. Targeting RAS–ERK signalling in cancer: promises and challenges. Nat. Rev. Drug Discov. 2014;13:928–42.
7. Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell beha viour, life and fate. Nat. Rev. Mol. Cell Biol. 2020;21:607–32.
8. Asati V, Mahapatra DK, Bharti SK, Pijić K, Akt/mTOR and ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur. J. Med. Chem. 2016;109:314–41.
9. Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–32.
10. Rokoski R Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharm. Res. 2019;142:151–68.
11. Savio P, Fava P, Casoni F, Cremona O. Targeting the ERK signaling pathway in melanoma. Int J Mol Sci. 2019;20:1483.
12. Bramanandam M, Filippo A, Suresh KR, Rakesh K. An inherent role of microtubule network in the action of nuclear receptor. Proc. Natl. Acad. Sci. USA. 2006;103:15981–6.
13. Wang X, Yang Z, Zhang H, Ding L, Li X, Zhu C, et al. The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT. Biochimica et. biophysica acta. 2008;1783:1220–8.
14. Bugide S, David N, Nair A, Kannan N, Samanthapudi VS, Prabhakar J, et al. Hematopoietic PBX-interacting protein (HIPP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics. Oncogene. 2015;34:4601–12.
15. Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J. Clin. Invest. 2013;123:630–45.
16. Feng Y, Li L, Zhang X, Zhang Y, Liang Y, Lv J, et al. Hematopoietic pre-B cell leukemia transcription factor interacting protein is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, migration, and invasion. Cancer Sci. 2016;107:1313–22.
17. Feng Y, Xu X, Zhang Y, Ding J, Wang Y, Zhang X, et al. HIPP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion. Sci. Rep. 2015;5:9429.
18. Khumukcham SS, Samanthapudi VSK, Penugurti V, Kumari A, Kesavan PS, Vela-tooru LR, et al. Hematopoietic PBX-interacting protein is a substrate and an inhibitor of the APC/C-Cdc20 complex and regulates mitosis by stabilizing cyclin B1. J. Biol. Chem. 2019;294:10236–52.
19. Nathan PJ, O’Neill BV, Napolitano A, Bullmore ET. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci. Ther. 2011;17:490–505.
20. Green DR. The coming decade of cell death research: five riddles. Cell. 2019;177:1094–107.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
22. Steeg PS. Targeting metastasis. Nat. Rev. Cancer. 2016;16:201–18.
23. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–91.
24. Roy-Luzarago M, Hodivala-Dilke K. Molecular pathways: endothelial cell FAK-A target for cancer treatment. Clin. Cancer Res. 2016;22:3718–24.
25. Mai H, Xu X, Mei G, Hong T, Huang J, Wang T, et al. The interplay between HPIP and casein kinase 1alpha promotes renal cell carcinoma growth and metastasis via activation of mTOR pathway. Oncogenesis. 2016;5:260.
26. Ji Q, Xu X, Kang L, Xu Y, Xiao J, Goodman SB, et al. Hematopoietic PBX-interacting protein mediates cartilage degeneration during the pathogenesis of osteoarthritis. Nat. Commun. 2019;10:313.
27. Shostak K, Patrascu F, Goktuna SI, Close P, Borgs L, Nguyen L, et al. MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation. Cell Death Differ. 2014;21:811–24.
28. Fraguas-Sanchez AI, Martin-Sabroso C, Torres-Suarez AI. Insights into the effects of the endocannabinoid system in cancer: a review. Br. J. Pharmacol. 2018;175:2566–80.
29. Pisanti S, Picardi P, D’Alessandro A, Laezza C, Bifulco M. The endocannabinoid signaling system in cancer. Trends Pharm. Sci. 2013;34:273–82.
30. Samataro D, Pisanti S, Santoro A, Gazzerro P, Malfittano AM, Laezza C, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol. Pharmacol. 2006;70:1298–306.
31. Fiore D, Ramesh P, Proto MC, Piscopo C, Franceschelli S, Anzelmo S, et al. Rimonabant kills colon cancer Stem cells without inducing toxicity in normal colon organoids. Front. Pharmacol. 2017;8:949.
32. Proto MC, Fiore D, Piscopo C, Franceschelli S, Bizzarro V, Laezza C, et al. Inhibition of Wnt/beta-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer. Sci. Rep. 2017;7:11678.
33. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27–47.
34. Martinez-Outschoorn UE, Peris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol. 2017;14:11–31.
35. Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J. Obes. 2009;34:547–56.

ACKNOWLEDGEMENTS
This work was supported by National Key Research Development Program of China (2017YFA0505602), National Natural Science Foundation (81630067, 81930078, 81872246, 81802756, 31470773 and 81773135) and Major New Drugs Innovation and Development (2018ZX0918102-002).

AUTHOR CONTRIBUTIONS
Q.Y., Z.Z., and L.D. designed the experiments and analyzed the data. P.L. and S.C. conducted all experiments and data analysis, aided by Y.H., Y.Z., J.L., X.C., L.Z., J.J., Z.J., and P.L. wrote the manuscript. Q.Y., Z.Z., and L.D. reviewed and edited the paper. Q.Y., L.L. Z.Z. conceived and directed the project. All authors read and approved the final manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS STATEMENT
All animal studies were performed strictly in accordance with the Animal Care Guidelines approved by the Institutional Animal Care Committee of Beijing Institute of Biotechnology.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00580-3.

Correspondence and requests for materials should be addressed to L.D., Z.Z., S.L. or Q.Y.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021